Alcoholics will be given ketamine-assisted therapy as part of a £2.4 million phase three trial to see if it helps them stay off alcohol for longer.
Alcoholics will be given ketamine-assisted therapy as part of a £2.4 million phase three trial to see if it helps them stay off alcohol for longer.
It comes after a phase two trial showed ketamine and therapy treatment was safe and tolerable for heavy drinkers. The Ketamine for Reduction of Alcohol Relapse trial will now move to the next step of drug development, with the aim of rolling it out into the NHS if it proves effective.It is also used as a recreational drug and is classified as a Class B banned substance by the Home Office.Half will be given ketamine at the dose used in the first clinical trial with psychological therapy.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Alcoholics to be given ketamine to see if it helps reduce heavy drinkingIt follows an earlier study which found participants who had ketamine combined with therapy stayed completely sober, representing 86% abstinence in the six-month follow-up.
Lire la suite »
Alcoholics in Manchester to receive ketamineManchester is one of seven locations involved in the trial
Lire la suite »
Researchers smell a cryptomining Chaos RAT targeting LinuxResearchers smell a cryptomining Chaos RAT targeting Linux systems
Lire la suite »
What are the patterns of symptoms and risk factors for Long COVID among SARS-CoV-2 infected individuals?What are the patterns of symptoms and risk factors for Long COVID among SARS-CoV-2 infected individuals? medrxivpreprint UUtah UCSF DukeMedSchool nyugrossman symptoms riskfactor longcovid covid COVID19 SARSCoV2
Lire la suite »
Research reveals the assembly dynamics of nucleocapsid protein condensates can be regulated by small molecules with therapeutic potentialResearch reveals the assembly dynamics of nucleocapsid protein condensates can be regulated by small molecules with therapeutic potential biorxivpreprint harvardmed Harvard virus coronavirus humancoronaviruses protein nucleocapsidprotein
Lire la suite »
Bioengineered soluble ACE2 for brain protection against SARS-CoV-2 infectionBioengineered soluble ACE2 for brain protection against SARS-CoV-2 infection biorxivpreprint NorthwesternU ChariteBerlin UChicago brain SARSCoV2 ACE2 COVID19 coronavirus covid
Lire la suite »